WANY
TBPH icon

Wealthspire Advisors (New York)’s Theravance Biopharma TBPH Stock Holding History

Wealthspire Advisors (New York)’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12
Closed -$175 – 2689
2025
Q3 		$175 Buy
+12
New +$152 ﹤0.01% 2951

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Wealthspire Advisors (New York)'s TBPH Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 12 shares — an estimated $175 sold.

Wealthspire Advisors (New York) first reported a position in TBPH in Q3 2025 and held it in 1 quarter. The position peaked at $175 in Q3 2025. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 12 Theravance Biopharma shares in Q4 2025, an estimated $175.
  • Wealthspire Advisors (New York) first reported a position in Theravance Biopharma in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Theravance Biopharma position peaked at $175 in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.